The funding will support ICER’s ongoing efforts to transform the way all new prescription drugs are evaluated and priced and will help advance the organization’s mission to ensure sustainable access to high-value care for all patients.
The new grant is LJAF’s latest investment in ICER, following a two-year, $5.2 million award made to the group in 2015 in support of its efforts to assess new drugs with the potential to significantly affect patient care and health system budgets.
Since that time, ICER has produced reports evaluating drugs intended to treat high cholesterol, non-small cell lung cancer, multiple sclerosis, atopic dermatitis, and other conditions.
“Previous funding from LJAF has allowed ICER to lead a national discussion about prescription drug pricing, and pharmaceutical companies are now beginning to reference ICER’s value-based benchmarks when launching new treatments in the U.S.,” ICER President Steve Pearson said. “However, prices for the majority of medicines still do not reflect the clinical benefit they deliver. By expanding the frequency, scope and reach of our value-based assessments, we will continue to move the country toward a more transparent healthcare system that rewards medical innovation while allowing patients to access the treatments they need.”